Morphic reloads
Why Morphic raised an $80M B round to ramp up development of integrin inhibitors
With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace.
Existing investor Omega Funds and new investor Novo Holdings A/S led the
